Author

T. L. Chang

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1

Frequent Co-Authors

A. Wang· 2 shared C. Xu· 2 shared A. Bakovic· 1 shared A. Beaulieu· 1 shared A. Lemenze· 1 shared A. Narayanan· 1 shared A. Rivera· 1 shared C. Cugini· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Wang

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Interferon epsilon restricts Zika virus infection in the female reproductive tract

C. Xu, A. Wang, L. Ebraham, L. Sullivan, C. Tasker, V. Pizutelli, J. Couret, C. Hernandez, P. Q. Deb, L. Fritzky, S. Subbian, N. Gao, Y. Lo, M. Salvatore, A. Rivera, , T. L. Chang

This study shows that IFNε protects against vaginal ZIKV infection in mice by maintaining epithelial integrity and is effective even without IFNAR1 signaling.

PNAS Nexus · Oct 25, 2023Peer-reviewedImmunology

Differential effects of antiseptic mouth rinses on SARS-CoV-2 infectivity in vitro

C. Xu, A. Wang, E. R. Hoskin, C. Cugini, K. Markowitz, T. L. Chang, D. H. Fine

This study evaluates the antiviral effects of mouth rinses on SARS-CoV-2 infectivity in vitro, finding that some products significantly reduce viral infectivity while others cause cytotoxicity.

bioRxiv · Dec 1, 2020Microbiology

Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2

A. Bakovic, K. Risner, N. Bhalla, F. Alem, T. L. Chang, W. Weston, J. A. Harness, A. Narayanan

This paper shows brilacidin, a synthetic small molecule, strongly inhibits SARS-CoV-2 in cell cultures and works well with remdesivir.

bioRxiv · Oct 29, 2020 · PreprintMicrobiology